Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 47Neutropenia 26Lymphoma 25Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Neoplasms 11Sarcoma 9Lymphoma, Follicular 9Ovarian Neoplasms 8Lymphoma, Mantle-Cell 8Leukemia 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Triple Negative Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Lymphoma, B-Cell, Marginal Zone 5Chemotherapy-induced Neutropenia 5Rhabdomyosarcoma 4Neoplasm Metastasis 4Lymphoma, Large-Cell, Immunoblastic 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Urinary Bladder Neoplasms 3Testicular Neoplasms 3Sarcoma, Synovial 3Prostatic Neoplasms 3Neurofibrosarcoma 3

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1Topotecan 1SAR125844 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Malignant Solid Tumors × pegfilgrastim × Clear all
NCT02805166 2016-06-17

PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 4 Completed
420 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡